Case report

Exquisite response to intravenous immunoglobulin in Susac syndrome during pregnancy

Enrique Gomez-Figueroa⁎,1, Sofia Garcia-Trejo1, Raul Anwar Garcia-Santos1, Gerardo Quiñones-Pesqueira1, Juan Manuel Calleja-Castillo1

Neurology Department, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico

ARTICLE INFO

Keywords:
Susac syndrome
Neuroinflammation
Corpus callosum
Demyelinating disease
Vasculitis

ABSTRACT

Introduction: From its initial report on two female patients in 1979 by J.O. Susac, Susac syndrome (SuS) or SICRET (small infarctions of cochlear, retinal and encephalic tissue) has persisted as an elusive entity. To date the available evidence for its treatment is based on case reports and case series. The largest systematic review described only 304 reported cases since the 1970s. Here we presented the first reported case to our knowledge in Mexican population and the unusual presentation in a pregnant patient.

Case presentation: A 34-year-old Hispanic woman was brought to the ER in our hospital for apathy and behavioral changes. Her husband described a one-month history of behavioral changes with apathy, progressive abulia, visuospatial disorientation, and gait deterioration. The initial lab test shows no significance except by a positive qualitative hCG. An MRI was obtained and showed hyperintense periventricular white matter lesions in T2 and FLAIR sequences also involving bilateral basal ganglia and with predominant affection of the corpus callosum, in addition to infratentorial cerebellar lesions. After treatment with intravenous immunoglobulins a marked and prompt clinical and radiological improvement was observed.

Conclusion: SuS is still an elusive disease. To date, no definitive score or clinical feature can predict the outcome of the disease. The presentation during pregnancy is also rare and therefore the optimal treatment and the prognosis is unknown. We hope that this article will serve as a foundation for future research.

1. Introduction

From its initial report on two female patients in 1979 by J.O. Susac, Susac syndrome (SuS) or SICRET (small infarctions of cochlear, retinal and encephalic tissue) has persisted as an elusive entity. To date the available evidence for its treatment is based on case reports and case series. The largest systematic review described only 304 reported cases since the 1970s [1]. Here we presented the first reported case to our knowledge in Mexican population and the unusual presentation in a pregnant patient.

2. Clinical case

A 34-year-old Hispanic woman was brought to the ER in our hospital for apathy and behavioral changes. She had no prior neurological or systemic disease, no exposure to toxic or vascular risk factors, and had suffered a self-limiting (3-days duration) episode of incapacitating vertigo 6 months prior and an episode of right ear tinnitus (2 days of duration) 2 months before hospitalization without receiving any medical care.

Upon arrival at the ER, her husband described a one-month history of behavioral changes with apathy, progressive abulia, visuospatial disorientation, and gait deterioration. Initial exploration revealed a patient with auto-activation apathy, monotonous and dysprosodic speech and bilateral corticospinal involvement with hyperreflexia and Babinski’s sign but no weakness.

The initial lab test shows no significance except by a positive qualitative hCG. The patient was unable to answer for any G/O history and her husband was also oblivious about it. An MRI was obtained and showed hyperintense periventricular white matter lesions in T2 and FLAIR sequences also involving bilateral basal ganglia and with predominant affection of the corpus callosum, in addition to infratentorial cerebellar lesions. Lesional restriction of diffusion but no contrast enhancement was observed. T1 weighted images showed hypointense lesions in the same topography (Fig. 1). Due to prominent pericallosal lesions with clinical findings of medial frontal syndrome and bilateral

⁎ Corresponding author at: Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, Insurgentes Sur 3877, Tlalpan, Mexico city, Mexico.
E-mail address: enriquefigueroa@comunidad.unam.mx (E. Gomez-Figueroa).

These authors contributed equally to the manuscript.

https://doi.org/10.1016/j.ensci.2017.12.004
Received 30 November 2017; Accepted 20 December 2017
Available online 22 December 2017
2405-6502/ © 2018 Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
corticospinal involvement of monophasic subacute evolution, primary vs secondary demyelinating disease was suspected. A lumbar puncture was performed resulting and CSF values showed proteins of 77 mg/dl, glucose of 52 mg/dl (serum glucose of 89 mg/dl), and no cells. Anti-AQP4 antibodies and oligoclonal bands were absent in CSF. A comprehensive workup for viral encephalitis and atypical infectious-disease result negative and cultures for fungi and bacteria. Also given the impossibility to further image studies as a complete CT and PET, a workup for paraneoplastic neurologic antibodies was obtained that was also negative Complete rheumatologic workup was negative except for 1: 2560 antinuclear antibodies in a speckled staining fine pattern without any systemic clinical correlate. Obstetric evaluation showed a normal development 15 weeks GA fetus.

Upon admission, 5 pulses of methylprednisolone were administered without obvious clinical improvement. Immunomodulatory treatment was escalated to intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 days. After treatment with IVIg, neuropsychiatric symptoms of medial frontal syndrome remitted, and the patient could cooperate for further study. Ophthalmologic assessment revealed retinal vasculitis corroborated by fluorescein angiography (FA) (Supplementary Fig. 1). Audiometric testing showed bilateral sensorineural hearing loss. A new MRI showed prior lesions to be smaller or absent, and the patient showed clinical improvement confirmed by neuropsychological testing. Once the diagnosis of SuS was established. The husband decided not to continue further with the pregnancy and a therapeutic abortion was performed, the patient was discharged for further treatment with oral steroids and CCF.

3. Discussion and conclusion

Here we discuss an atypical patient with the unusual diagnosis of Susac syndrome in a Mexican woman who was also in the first trimester of pregnancy. The anatomical basis of the clinical diagnosis as a subacute and evolving frontal syndrome in a young woman guide or workup to focus in autoimmune disorders, demyelinating disorders and structural lesions. The MRI allows to focus on the overview of predominantly callosal disease.

Differential diagnosis of corpus callosum lesions includes demyelinating, non-demyelinating inflammatory lesions, and transient splenial lesions. Demyelinating lesions include MS, neuromyelitis optica and ADEM, all of which were discarded in this patient based on the respective criteria for each one. Non-demyelinating inflammatory lesions include Sus and CNS vasculitis [2]. It is particularly important to differentiate Sus from MS. In Sus, lesions of the corpus callosum are typically centrally located, while the lesions in MS and ADEM involve the undersurface at the septal interface, in MS, these lesions are often extended around the venules of the brain, resulting in a finger-like appearance (“Dawson fingers”), while lesions appear circular in Sus. Typically, these callosal lesions involve the central fibers and spare the periphery [3] MRI reveals widespread abnormalities of the corpus callosum, manifested as small central holes, particularly in the splenium. Linear defects of the corpus callosum can also be detected, the so-called “spokes”, representing microinfarctions of obliquely radiating axons [4]. The localization of the lesions is probably explained by the angioarchitecture of the corpus callosum. The inflammation and occlusion of the small precapillary arterioles with a diameter under 100 μm result in infarction of the central portion, but not the undersurface of the corpus callosum [4]. Subsequent documented involvement of retinal vasculitis and vestibulocochlear damage established the diagnosis in our patient.

Sus is currently considered a vasculitis with predominantly endothelial affection of autoimmune origin probably mediated by endothelial cell antibodies (AECA), with subsequent response by complement with C4d deposits, “mummification” phenomena, and endothelial necrosis [5]. Nevertheless, a study showed that in fact only 30% of patients with definite Sus have AECA, suggesting that AECA represent a secondary phenomenon in an etiologically heterogeneous syndrome, with a pathogenesis still far from fully understood [6].

Diagnosis of Sus is predominantly clinical and based on the evidence of the originally described triad with encephalic, retinal and vestibulocochlear affection. The clinical features include encephalopathy that is characterized by headache that may be migrainous or oppressive. Headache often occurs up to six months before the onset of the other symptoms. It is probably due to an affection of the leptomeningeal vessels. The other symptoms of encephalopathy have a stroke-like or subacute onset, with neuropsychological deficits, bladder disturbance, long tract signs, focal neurological signs, seizures, and often disturbance of consciousness [1]. The hearing loss can be a dramatic and severely disabling feature of Susac syndrome. It often occurs overnight and may affect both ears. A loss of the low or middle frequencies is typical, but loss of high frequencies can also occur. The severe hearing loss is often accompanied by vertigo and a roaring tinnitus. The hearing loss is caused by occlusion of the cochlear pre-capillary arterioles and those of the semicircular canal. Hearing loss is often irreversible and may require cochlear implants or hearing devices for a whole life [7]. Typical findings in patients with Sus include branch retinal artery occlusions (BRAO) detectable on retinal fluorescein angiography, the occlusions may affect the periphery and may not lead to clinical symptoms, but they can also affect the larger branches resulting in visual field deficits. Many patients complain about blurred vision or photopsia [7]. MRI, retinal fluorescein angiography, and audiometry are considered crucial tests to enable diagnosis.

In 2016, specific diagnostic criteria based on a cohort of 32 patients was proposed: Definitive Sus requires involvement of these 3 systems [8]. Being a rare disease, the clinical course and prognosis is largely unknown. Based on empirical stratification [9] the course can be monocular, polyocular and chronic-continuous with a cutoff parameter of 2 years separating the monocular course from the other forms.

Many treatment approaches for Sus have been described in case
| Cases | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|
| Published by | Gordon 1991<sup>8</sup> | McDuff 1987<sup>2</sup> | Hua 2014<sup>10</sup> | Ionnides 2013<sup>11</sup> | Engelholm 2013<sup>12</sup> | Antulov 2014<sup>13</sup> | Feresiadou 2014<sup>14</sup> | Our case |
| Origin | US   | Canada | US   | Australia | Germany | Croatia | Sweden | Mexico |
| Age | 28   | 31   | 25   | 13   | 32   | 21   | 35   | 37   |
| Gestational age at onset (weeks) | 14   | No specified | 13   | 32   | 35   | 15   | 15   |
| Previous medical history | None | None | None | Epilepsy from a perinatal ischaemic event | None | None | Apparent similar clinical picture at 12 yo, treated with steroids | None |
| System of onset | Eye Unilateral weakness, dysarthria and apathy | Eye Ataxia and dysarthria | Auditory Amnestic syndrome, Gait disorder, Bilateral severe weakness | Neurologic Bilateral severe weakness and dysarthria | Neurologic Bilateral severe weakness and progressive cognitive affection | Auditory None | Auditory Cognitive affection (frontal medial syndrome) and bilateral weakness | None |
| Neurologic symptoms | Visual field deficit | Visual field deficit | Loss of visual acuity | Loss of visual acuity | Visual field deficit | Loss of visual acuity | Loss of visual acuity |
| Auditory symptoms | Bilateral neurosensorial hearing loss | Bilateral tinnitus and neurosensorial hearing loss | Tinnitus | Right neurosensorial hearing loss | Neurosensorial hearing loss | Left neurosensorial hearing loss | Tinnitus and bilateral neurosensorial hearing loss |
| Ophthalmologic symptoms | None | None | Cervical cord involvement | None | Livedo racemosa | None | None |
| Time until fully triad (months) | 1 | 2 | 6 | 4 | 1.5 | Not completed | Not completed | 6 |
| MRI findings | No | Not done | Yes | Yes | Yes | Yes | No | Yes |
| Deep grey matter | No | Not done | Yes | Callosal and periventricular lesions | Callosal | Callosal and periventricular lesions | Callosal and periventricular lesions | Callosal |
| White matter | No | Not done | Yes | No, but also reported meningeal enhancement | No | No | No | No |
| Posterior fossa involvement | No | Not done | Yes | No reported | Yes | No reported | No | Yes |
| Gadolinium enhancement | No reported | No reported | Yes | No reported | Yes | No reported | No | Yes |
| CSF findings | Proteins mg/dl | Gels (Mono) | No reported | 252 | 95 | 9 | 2000 | 300 |
| Initial treatment | Heparin | Partial | None | IVMP × 5 | Partial | PLEX and IVg | IGIV × 5 | IVMP × 5 |
| Treatment | Response | Partial | None | Partial | Oral prednisone | MMF | Partial | Partial |
| 2nd line treatment | None | None | Oral prednisone | None | Oral prednisone | MMF + MTX | Almost complete recovery | Complete response |
| Chronic treatment | None | None | Partial remission | IVMP × 3 | No response | IVMP × 5 | AZA | Partial |
| Response | Warfarin | Almost complete recovery | Partial remission | No response | MMF | Almost complete recovery | Almost complete recovery | CGF |
| Prognosis | 0.2 | 4 | Mild hearing loss | 1.5 | Cognitive deficit with visuospatial and word recall | 3.5 | No specified | 1 |
| Follow up (years) | | | | | | | | |
| Sequels | Visual deficit | 4 | Mild hearing loss | 1.5 | Cognitive deficit with visuospatial and word recall | 3.5 | No specified | 1 |
| Course of disease | Healthy product | Monocyclic | Therapeutic abortion at 15 weeks GA | Chronic continuous | Monocyclic | Healthy product | Probably Monocyclic | Healthy product |
| Final pregnancy state | Healthy product | Monocyclic | Healthy product | Monocyclic | Healthy product | Monocyclic | Healthy product |

Table 1: Comparison of data of the different reported cases of Susac syndrome with onset in pregnancy.
reports and series, but rigorous analysis of these therapies is limited by inconsistent and often incomplete reports. In the acute period, treatment with steroids, IVIg, plasma exchange, and even rituximab has been reported with predominantly successful response [10]. Antithrombotic agents and nimodipine have also been used, aiming to maintain blood flow and prevent vasospasm [7]. Optimal chronic management and duration of treatment is unknown, yet the decision to withdraw treatment must incorporate surveillance brain MRI and FA findings in addition to clinical symptoms and signs.

We have managed to find 7 cases previously reported in the literature in English and in Spanish of cases that have started with Susac syndrome during pregnancy [11–17] (Table 1). Unfortunately, the behavior of the disease is heterogeneous. Dr. Aubert-Cohen et al. have also managed to report the behavior of the disease before and after pregnancy in 4 patients. Obviously, the low frequency of the disease does not allow obtaining any statistically significant result. But we hope that this article will serve as a foundation for future research.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ensci.2017.12.004.

Contributions

Dr. Calleja-Castillo was in charge of the diagnosis, treatment care and follow up of the patient and supervised the elaboration of the manuscript. Dr. Gomez-Figueroa prepared the draft. All authors were part of the patient care team and approved the final submitted version.

Written consent to publish was obtained from the patient.

Conflict of interest

All authors declare no competing interests or external funding.

References

[1] J. Dörr, S. Krautwald, B. Wildemann, et al., Characteristics of Susac syndrome: a review of all reported cases, Nat. Rev. Neurol. 9 (2013) 307–316.
[2] N. Gaig, S.W. Reddel, D.H. Miller, et al., The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases, J. Neurol. Neurosurg. Psychiatry 0 (2015) 1–9.
[3] I. Kleffner, M. Deppe, S. Mohammad, Neuroimaging in Susac's syndrome: focus on DTI, J. Neurol. Sci. 299 (2010) 92–96.
[4] I. Kleffner, et al., A brief review of Susac syndrome, J. Neurol. Sci. 322 (2012) 35–40.
[5] J.O. Susac, et al., Susac's syndrome: 1975–2005 microangiopathy/autoimmune endotheliopathy, J. Neurol. Sci. 257 (1) (2007) 270–272.
[6] Jarius et al., Clinical, paraclinical and serological finding in Susac syndrome: an international multicenter study, J. Neuroinflammation 11 (2014) 46.
[7] V. Vishnevskia-dai, J. Chapman, R. Sheinfeld, Susac syndrome: clinical characteristics, clinical classification, and long-term prognosis, Medicine (Baltimore) 95 (2016) e5223.
[8] I. Kleffner, J. Dörr, M. Ringelstein, et al., Diagnostic criteria for susac syndrome, Neurö. Neurosurg. Psychiatry 87 (2016) 1287–1295.
[9] R.M. Rennebohm, R.A. Egan, J.O. Susac, Treatment of Susac's syndrome, Curr. Treat. Options Neurol. 10 (2008) 67–74.
[10] I. Vodovipec, S. Prasad, Treatment of Susac syndrome, Curr. Treat. Options Neurol. 18 (2016) 3–8.
[11] D.L. Gordon, S.S. Hayreh, H.P. Adams Jr., Microangiopathy of the brain, retina, and ear: improvement without immunosuppressive therapy, Stroke 22 (1991) 933–937.
[12] D.J. MacFadyen, R.J. Schneider, I.A. Chisholm, A syndrome of brain, inner ear and retinal microangiopathy, Can. J. Neurol. Sci. 14 (1987) 315–318.
[13] Hua, L.H. et al. A case of Susac syndrome with cervical spinal cord involvement on MRI, J. Neurol. Sci., 337, 1, 228–231.
[14] Z.A. Ioannides, C. Airey, N. Fagermo, et al., Susac syndrome and multifocal motor neuropathy first manifesting in pregnancy, Aust. N. Z. J. Obstet. Gynaecol. 53 (2013) 314–317.
[15] M. Maik Engeholm, B. Leo-Kottler, H. Rempp, et al., Encephalopathic Susac's syndrome associated with livedo racemosa in a young woman before the completion of family planning, BMC Neurol. 13 (185) (2013).
[16] R. Antulov, I. Holjar-Erlic, O. Perkovic, et al., Susac's syndrome during pregnancy—the first Croatian case, J. Neurol. Sci. 341 (1–2) (2014) 162–164.
[17] A. Feresiadou, U. Eriksson, H.–C. Larsen, et al., Recurrence of Susac syndrome following 23 years of remission, Case Rep. Neurol. 6 (2014) 171–175.